Lidoderm Antitrust Litigation

In re: Lidoderm Antitrust Litigation Case No. 14-md-02521-WHO

Settlement Fund:            $96,000,000
Settlement Period:          August 23, 2012 – August 1, 2014
Claim Filing Deadline:     October 1, 2018


There are currently a number of active antitrust settlements and lawsuits that fall into the category of “pharmaceutical settlements.” Under these settlements, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices. The prices were allegedly manipulated as a result of anticompetitive practices undertaken by the drug manufacturers.

Plaintiffs claim that Defendants’ actions denied Indirect Purchasers who paid for Aggrenox the benefits of competition and caused them to pay higher prices for Aggrenox than they otherwise would have paid.

Organizations that have a self-insured benefits plan are eligible if, as a third-party payor, the plan, at any time from August 23, 2012 to August 1, 2014, purchased, paid and/or reimbursed for some or all of the purchase price for Lidoderm and/or its generic versions. Purchases could have been for employees, insureds, participants, or beneficiaries covered under your benefits plan.

To be eligible, the transaction must have taken place in any of the following locations:

  • Arizona, California, Florida, Kansas, Maine, Massachusetts, Minnesota, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee, West Virginia, or Wisconsin

Next Steps for MCAG Clients

Data is often required to complete your claim for settlements in this category. MCAG can quickly review the process with you so we can easily obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements. Should you wish to proceed, please contact an Account Manager at 800.355.0466 or send an email to